The global Heart Defects Closure Device Market Report contains analysis for Patent Foramen Ovale Closure Devices and Atrial & Ventricular Septal Defect Closure Devices. The global patent foramen ovale closure device market size is estimated to increase over the forecast period to reach $322.7 million by 2027. The global atrial & ventricular septal defect closure device (ASD & VSD) market size is estimated to increase over the forecast period to reach $226.2 million by 2027.

Abbott and W.L. Gore were the share leaders in the global patent foramen ovale closure device (PFO) market and the global atrial & ventricular septal defect closure device market. This global analysis covers over 70 countries and includes in-depth procedure numbers by the country for each market.

The patent foramen ovale closure devices treat patent foramen ovale (PFO), a defect in the septum between the two atrial chambers of the heart. Overall, the market is expected to increase over the forecast period despite long-term clinical data limitations. The atrial and ventricular septal defect closure devices are inserted into the defect and expand to form a seal around the defect. Most of the time these devices allow the heart tissue to grow over the device with time. Overall, the market is expected to increase over the forecast period despite the declining ASPs and multiple competitors within the space.

MARKET DATA INCLUDED

• Unit Sales, Average Selling Prices, Market Size & Growth Trends
• Procedure Numbers
• COVID-19 Impact Analysis
• Market Drivers & Limiters
• Market Forecasts Until 2027, and Historical Data to 2017
• Recent Mergers & Acquisitions
• Disease Overviews
• Company Profiles, Product Portfolios, and SWOT for Top Competitors

Procedure Numbers 

Procedure numbers for the heart defects closure device market include patent foramen ovale (PFO) devices and atrial and ventricular septal defect (ASD & VSD) closure devices are included. PFO closure procedures are performed in the heart catheterization lab by a cardiologist. ASD and VSD closure procedures are performed in the heart catheterization lab by a cardiologist. For both, the procedure numbers are divided by country with an in-depth analysis including information ranging from 2017 to 2027. The atrial and ventricular septal defect (ASD & VSD) closure devices are segmented into the atrial septal defect closure device market and ventricular septal defect closure device market.

Patent Foramen Ovale Closure Device Market Insights

Moderate growth over the forecast period is projected for the patent foramen ovale closure device market. PFOs are present in 20-25% of the population and are significantly more prevalent in patients who have had a stroke. PFO closure has also been seen to potentially benefit migraine sufferers as 25% of these patients have PFOs. The large patient population will drive this market and enable it to experience growth. PFO procedures are minimally invasive and because of this, they are favored as they reduce pain and the duration of hospital stays. However, the lack of clinical data and the low diagnosis rate for patients with PFO limit this market and challenge the growth rate.

Atrial and Ventricular Septal Defect Closure Device Market Insights

The global market for atrial (ASD) and ventricular septal defect (VSD) closure devices is driven primarily by sales of atrial septal defect closure devices. Units sold are dependent on the number of ASD and VSD procedures done annually. As procedure numbers experience modest growth over the forecast period, so do unit sales. With a growing global population, the number of patients requiring ASD/VSD is expected to increase. Similarly, as more doctors become comfortable performing these procedures, the market for the devices will increase. The limited patient population along with market saturation limit the market and slow the rate of unit sales growth and the number of devices sold. Despite this, the overall market is expected to increase over the forecast period.

MARKET SHARE INSIGHTS

Abbott and W.L. Gore controlled the global patent foramen ovale closure device and the atrial and ventricular septal defect closure device markets. In 2020, Abbott was the leading competitor in the market for PFO devices. The Amplatzer™ PFO Occluder received CE Mark approval in 1998. In 2020, Abbott was the leading competitor for ASD and VSD devices. For ASD devices, Abbott offers the Amplatzer™ Septal Occluder, which is a minimally invasive device using transcatheter for replacement. The Amplatzer™ Muscular VSD Occluder is the VSD device that Abbott offers.

RESEARCH REGIONAL COVERAGE

Throughout this report, iData Research has covered over 70 countries across the globe in great detail. Each global region may be purchased as a stand-alone report, tailoring the data to your needs. The regions covered are:

• North America (the United States and Canada)
• Latin America (Brazil, Mexico, Colombia, Argentina, Peru, Chile, Venezuela, and Other)
• Western Europe (Germany, France, Italy, Spain, Switzerland, Austria, Portugal, Benelux, Scandinavia, and Other)
• Central and Eastern Europe (Poland, Turkey, Russia, Greece, Czech Republic, Croatia, Bulgaria, Ukraine, Kazakhstan, Hungary, Romania, Baltic States (Estonia, Latvia, and Lithuania), and Other)
• Middle East (Saudi Arabia, UAE, Israel, Iran, Kuwait, Qatar, Bahrain, Oman, and Other)
• Asia Pacific (China, Japan, South Korea, India, Australia, Singapore, Indonesia, Malaysia, Thailand, the Philippines, Brunei, Myanmar, Cambodia, Vietnam, New Zealand, Taiwan, Hong Kong, and Other)
• Africa South Africa, Egypt, Morocco, Ghana, Nigeria, Libya, Sudan, Uganda, Kenya, and Other)

FREE Sample Report